SCHEMBL952522

SCHEMBL952522

COC(=O)c1sc(-c2c(C)nn3ccccc23)nc1-c1ccc(F)cc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
F2RL3 Q96RI0 1/20 0.38
RAB9A P51151 1/20 0.36
ALPL P05186 1/20 0.36
CTSA P10619 3/20 0.35
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
HSD17B10 Q99714 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
PLA2G2A P14555 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C19 P33261 1/20 0.34
GRM5 P41594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956090 0.90 PTGS1 (0.36) CDC7DBF4F2RL3RAB9ACTSA
SCHEMBL953770 0.89 CDC7 (0.42) CDC7DBF4F2RL3RAB9APTGS1
SCHEMBL953628 0.86 TRPM8 (0.42) CDC7DBF4F2RL3KDM4EALDH1A1
SCHEMBL953824 0.86 NPC1 (0.37) CDC7DBF4F2RL3RAB9AKDM4E
SCHEMBL951855 0.84 TSHR (0.36) F2RL3RAB9ACTSAKDM4EIRAK4
SCHEMBL957443 0.82 TSHR (0.39) RAB9AKDM4EALDH1A1GAAHSD17B10
SCHEMBL953252 0.82 ALDH1A1 (0.38) CDC7DBF4RAB9AKDM4EALDH1A1
SCHEMBL958092 0.82 TRPM8 (0.38) CDC7DBF4RAB9AKDM4EALDH1A1
SCHEMBL953635 0.81 CDC7 (0.47) CDC7DBF4RAB9AKDM4EALDH1A1
SCHEMBL953230 0.81 LMNA (0.39) CDC7DBF4RAB9AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
US-9090601-B2 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003807-A1 Thiazole derivatives MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003807-A1 Thiazole derivatives MTOR, RICTOR, AKT2 CDC7 601/4885DBF4 3288/4885F2RL3 4796/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885F2RL3 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.